Cargando…

Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980–1994

The purpose of the study was to calculate population-based survival rates for osteosarcoma (OS) and Ewing's sarcoma (ES) in Great Britain during 1980–1994, determine proportions of patients treated at specialist centres or entered in national and international clinical trials, and investigate e...

Descripción completa

Detalles Bibliográficos
Autores principales: Stiller, C A, Passmore, S J, Kroll, M E, Brownbill, P A, Wallis, J C, Craft, A W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361067/
https://www.ncbi.nlm.nih.gov/pubmed/16317433
http://dx.doi.org/10.1038/sj.bjc.6602885
_version_ 1782153133152010240
author Stiller, C A
Passmore, S J
Kroll, M E
Brownbill, P A
Wallis, J C
Craft, A W
author_facet Stiller, C A
Passmore, S J
Kroll, M E
Brownbill, P A
Wallis, J C
Craft, A W
author_sort Stiller, C A
collection PubMed
description The purpose of the study was to calculate population-based survival rates for osteosarcoma (OS) and Ewing's sarcoma (ES) in Great Britain during 1980–1994, determine proportions of patients treated at specialist centres or entered in national and international clinical trials, and investigate effects of these factors on survival. Data on a population-based series of 1349 patients with OS and 849 with ES were compiled from regional and national cancer registries, UK Children's Cancer Study Group, regional bone tumour registries and clinical trials. Follow-up was through population registers. Survival was analysed by actuarial analysis with log-rank tests and by Cox's proportional hazards analysis. Five-year survival rates during 1980–1984, 1985–1989 and 1990–1994 were 42% (95% CI: 37, 46), 54% (95% CI: 50, 59) and 53% (95% CI: 48, 57), respectively, for OS and 31% (95% CI: 26, 37), 46% (95% CI: 40, 51) and 51% (95% CI: 45, 57) for ES. Proportions of patients treated at a supraregional bone tumour centre or a paediatric oncology centre in the three quinquennia were 36, 56 and 67% for OS and 41, 60 and 69% for ES. In 1983–1992, 48% of OS patients were entered in a national trial; for ES, 27% were entered in 1980–1986 and 54% in 1987–1994. Survival was similar for trial and nontrial patients with OS. For ES, trial patients had consistently higher 5-year survival than nontrial patients: 1980–1986, 42 vs 30%; 1987–1992, 59 vs 42%; 1993–1994, 54 vs 43%. During 1985–1994, patients with OS or ES whose main treatment centre was a nonteaching hospital had lower survival rates. In multivariate analyses of patients diagnosed during 1985–1994 that also included age, sex, primary site, surgical treatment centre, the results relating to main treatment centre for both OS and ES retained significance but the survival advantage of trial entry for ES became nonsignificant. For both OS and ES diagnosed since 1985, patients whose main treatment centre was a nonspecialist hospital had a lower survival rate.
format Text
id pubmed-2361067
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23610672009-09-10 Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980–1994 Stiller, C A Passmore, S J Kroll, M E Brownbill, P A Wallis, J C Craft, A W Br J Cancer Clinical Study The purpose of the study was to calculate population-based survival rates for osteosarcoma (OS) and Ewing's sarcoma (ES) in Great Britain during 1980–1994, determine proportions of patients treated at specialist centres or entered in national and international clinical trials, and investigate effects of these factors on survival. Data on a population-based series of 1349 patients with OS and 849 with ES were compiled from regional and national cancer registries, UK Children's Cancer Study Group, regional bone tumour registries and clinical trials. Follow-up was through population registers. Survival was analysed by actuarial analysis with log-rank tests and by Cox's proportional hazards analysis. Five-year survival rates during 1980–1984, 1985–1989 and 1990–1994 were 42% (95% CI: 37, 46), 54% (95% CI: 50, 59) and 53% (95% CI: 48, 57), respectively, for OS and 31% (95% CI: 26, 37), 46% (95% CI: 40, 51) and 51% (95% CI: 45, 57) for ES. Proportions of patients treated at a supraregional bone tumour centre or a paediatric oncology centre in the three quinquennia were 36, 56 and 67% for OS and 41, 60 and 69% for ES. In 1983–1992, 48% of OS patients were entered in a national trial; for ES, 27% were entered in 1980–1986 and 54% in 1987–1994. Survival was similar for trial and nontrial patients with OS. For ES, trial patients had consistently higher 5-year survival than nontrial patients: 1980–1986, 42 vs 30%; 1987–1992, 59 vs 42%; 1993–1994, 54 vs 43%. During 1985–1994, patients with OS or ES whose main treatment centre was a nonteaching hospital had lower survival rates. In multivariate analyses of patients diagnosed during 1985–1994 that also included age, sex, primary site, surgical treatment centre, the results relating to main treatment centre for both OS and ES retained significance but the survival advantage of trial entry for ES became nonsignificant. For both OS and ES diagnosed since 1985, patients whose main treatment centre was a nonspecialist hospital had a lower survival rate. Nature Publishing Group 2006-01-16 2005-11-29 /pmc/articles/PMC2361067/ /pubmed/16317433 http://dx.doi.org/10.1038/sj.bjc.6602885 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Stiller, C A
Passmore, S J
Kroll, M E
Brownbill, P A
Wallis, J C
Craft, A W
Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980–1994
title Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980–1994
title_full Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980–1994
title_fullStr Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980–1994
title_full_unstemmed Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980–1994
title_short Patterns of care and survival for patients aged under 40 years with bone sarcoma in Britain, 1980–1994
title_sort patterns of care and survival for patients aged under 40 years with bone sarcoma in britain, 1980–1994
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361067/
https://www.ncbi.nlm.nih.gov/pubmed/16317433
http://dx.doi.org/10.1038/sj.bjc.6602885
work_keys_str_mv AT stillerca patternsofcareandsurvivalforpatientsagedunder40yearswithbonesarcomainbritain19801994
AT passmoresj patternsofcareandsurvivalforpatientsagedunder40yearswithbonesarcomainbritain19801994
AT krollme patternsofcareandsurvivalforpatientsagedunder40yearswithbonesarcomainbritain19801994
AT brownbillpa patternsofcareandsurvivalforpatientsagedunder40yearswithbonesarcomainbritain19801994
AT wallisjc patternsofcareandsurvivalforpatientsagedunder40yearswithbonesarcomainbritain19801994
AT craftaw patternsofcareandsurvivalforpatientsagedunder40yearswithbonesarcomainbritain19801994